Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2011

View Archived Issues

Ortho-McNeil-Janssen discloses new gamma-secretase modulators

Tempero Pharmaceuticals presents novel histone deacetylase 9 inhibitors

Apricus seeks approval in Latin America for topical erectile dysfunction drug

New lysophospholipid S1P1 receptor agonists claimed

Stiefel submits NDA for tazarotene foam

Johns Hopkins receives NIH funding for 5-year research project

Pseudotyped VLP-based vaccines show promise against hepatitis C

Sanofi discovers novel CaMK-II subunit delta inhibitors

CR-845 advances in new phase II trial in postoperative pain

Intercept Pharmaceuticals and Servier enter diabetes collaboration

FDA approves generic levetiracetam injection

Scientists to assess biomarkers in ProTECT trial participants

Arena Pharmaceuticals and Eisai report on lorcaserin carcinogenicity study

Meridian Bioscience launches new rapid test for CDI in Europe

Quidel molecular RT-PCR assay obtains CE mark approval

U.S. Department of Defense contracts Neuralstem to develop brain tumor therapy

Helsinn Therapeutics begins ROMANA 1 and 2 trials in NSCLC-related cachexia

MMV identifies new antimalarial aminopyridine derivatives

Stellar Biotech and Sigma-Aldrich collaborate for keyhole limpet hemocyanin

NanoViricides provides pipeline update and plans first IND submission

DelMar Pharmaceuticals receives Canada Industrial Research Assistance Program funding

New radioimmunotherapy enters phase I evaluation in HER2-positive intra-abdominal cancers

Histone deacetylase 6 inhibitor reverses symptoms of Charcot-Marie-Tooth disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...